Next Article in Journal
Longitudinal Assessment of Antimicrobial Susceptibility among Gram-Negative and Gram-Positive Organisms Collected from Italy as Part of the Tigecycline Evaluation and Surveillance Trial between 2004 and 2011
Next Article in Special Issue
Glioblastoma Multiforme Therapy and Mechanisms of Resistance
Previous Article in Journal
Metabolic Interactions of Purine Derivatives with Human ABC Transporter ABCG2: Genetic Testing to Assess Gout Risk
Previous Article in Special Issue
Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
Open AccessReview

Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes

1
Department of Biochemistry, University of Puerto Rico, San Juan, Puerto Rico 00935, USA
2
Comprehensive Cancer Center & Department of Biochemistry, University of Puerto Rico, San Juan, Puerto Rico 00935, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(11), 1361-1380; https://doi.org/10.3390/ph6111361
Received: 12 September 2013 / Revised: 24 October 2013 / Accepted: 28 October 2013 / Published: 4 November 2013
(This article belongs to the Special Issue Chemotherapeutic Agents)
Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery, and therapeutic effectiveness of several anticancer agents. The expansion of novel nanoparticles for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies, including small interference RNA (siRNA) and microRNA (miRNAs)-based molecules. In this review, we focus on the currently available drug delivery systems for anticancer agents. In addition, we will discuss the promising use of nanoparticles for novel cancer treatment strategies. View Full-Text
Keywords: nanoparticles; nanoliposomes; RNAi; miRNA; siRNA nanoparticles; nanoliposomes; RNAi; miRNA; siRNA
Show Figures

Figure 1

MDPI and ACS Style

Díaz, M.R.; Vivas-Mejia, P.E. Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. Pharmaceuticals 2013, 6, 1361-1380.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop